CSPC Innovation Pharmaceutical Co., Ltd. Class A

CSPC Innovation Pharmaceutical Co., Ltd. Class A

SSZSE:300765
32.22
CNY
-0.46
(-1.41%)
0.85EPS
66.19P/E
66.28BMarket Cap
Mar 12Next Earn

Total Valuation

CNY

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A carries a market capitalization of 66.28B, placing it among publicly traded companies globally. Its enterprise value stands at 65.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap66.28B
Enterprise Value65.02B

Important Dates

CSPC Innovation Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for March 12, 2027.

Earnings Date3/12/2027

Share Statistics

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A has 1.40B shares outstanding.

Shares Outstanding1.40B

Valuation Ratios

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 66.19. The price-to-sales ratio is 14.47, and the price-to-book ratio stands at 17.05.

PE Ratio66.19
PS Ratio14.47
PB Ratio17.05
P/TBV Ratio18.04

Enterprise Valuation

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 53.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 14.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 53.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 65.02B versus a market cap of 66.28B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales14.32
EV / EBITDA53.16
EV / EBIT53.16

Financial Position

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.45, indicating elevated leverage, while an interest coverage ratio of 28.61 demonstrates strong ability to service its debt obligations.

Current Ratio1.45
Quick Ratio0.72
Debt / Equity18.45
Debt / EBITDA0.65
Interest Coverage28.61

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 26.14, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 25.38 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.95, useful for judging operating efficiency across full business cycles. The company generates approximately 1.92M in revenue per employee across its workforce of 2,369.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.73 indicates how many times CSPC Innovation Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)26.14
Return on Assets (ROA)13.82
Return on Invested Capital (ROIC)25.38
Return on Capital Employed (ROCE)17.95
Revenue Per Employee1.92M
Employee Count2,369.00
Inventory Turnover3.73

Taxes

CNY

Over the twelve months ended September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A recorded 33.41M in income tax expense. That works out to an effective tax rate of 2.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.22B, leaving 992.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax33.41M
Effective Tax Rate2.74

Stock Price Statistics

CNY

As of the close on November 17, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A's stock has declined approximately 4.73% over the past 52 weeks. The 50-day moving average sits at 41.23, while the 200-day moving average is 35.69.

52-Week Price Change-4.73%
50-Day Moving Average41.23
200-Day Moving Average35.69

Income Statement

CNY

Over the twelve months ended September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A generated 4.54B in revenue and converted that into 992.78M in net income, yielding earnings per share of 0.85. EBITDA reached 1.22B, while operating income came in at 1.29B.

Revenue4.54B
Gross Profit3.03B
Operating Income1.29B
Pretax Income1.22B
Net Income992.78M
EBITDA1.22B
EBIT1.22B
Earnings Per Share (EPS)0.85

Balance Sheet

CNY

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A holds 2.46B in cash and equivalents against 792.49M in total debt, resulting in a net debt position of -789.13M. Total book value stands at 3.89B, with working capital of 1.54B providing operational flexibility.

Cash & Cash Equivalents2.46B
Total Debt792.49M
Net Debt-789.13M
Equity (Book Value)3.89B
Book Value Per Share2.77
Working Capital1.54B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-613.09M

Margins

Over the twelve months ended September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A posted a gross margin of 66.72, reflecting its pricing power and cost economics. The operating margin of 28.34 and net profit margin of 21.86 provide insight into operational efficiency.

Gross Margin66.72
Operating Margin28.34
Pretax Margin26.83
Profit Margin21.86
EBITDA Margin26.93

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of 0.72 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.87, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CSPC Innovation Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.01
Payout Ratio0.72
Shareholder Yield0.87

Stock Splits

CSPC Innovation Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 25, 2024 with a 5:6 split ratio.

Last Split Date4/25/2024
Split Ratio5:6

Scores

As of September 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 11.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score11.89